Adaptive Anti-MICA Antigen Binding Fragments for Extreme Environments

Publication ID: 24-11857571_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Adaptive Anti-MICA Antigen Binding Fragments for Extreme Environments,” Published Technical Disclosure No. 24-11857571_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857571_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,571.

Summary of the Inventive Concept

This inventive concept adapts anti-MICA antigen binding fragments for specific, narrow markets and unique operational environments, enhancing their effectiveness in extreme weather conditions, high-security settings, and disaster relief scenarios.

Background and Problem Solved

The original patent disclosed anti-MICA antigen binding fragments, but these fragments have limitations in certain environments. This new inventive concept addresses these limitations by providing specialized variations and niche solutions, enabling the effective detection and treatment of MICA-expressing cancer cells in extreme weather conditions, high-security environments, and disaster relief scenarios.

Detailed Description of the Inventive Concept

The inventive concept comprises a system for detecting MICA-expressing cancer cells in extreme weather conditions, featuring a polynucleotide encoding an anti-MICA chimeric antigen receptor (CAR) and a weather-resistant detector unit. Additionally, the concept includes a method for treating MICA-expressing cancer cells in a high-security environment, utilizing an anti-MICA CAR-expressing cell and a secure communication network. Furthermore, a disaster relief kit is proposed, comprising a portable container housing an anti-MICA CAR-expressing cell, a portable detector unit, and a communication device for contacting emergency services.

Novelty and Inventive Step

The new claims introduce novel and non-obvious elements, such as weather-resistant detector units, secure communication networks, and portable disaster relief kits, which significantly enhance the functionality and applicability of the original anti-MICA antigen binding fragments.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include adapting the anti-MICA CAR-expressing cells for use in space exploration, developing miniaturized detector units for wearable devices, or integrating the secure communication network with existing emergency response systems.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the fields of cancer treatment, disaster relief, and high-security medical services, with potential applications in extreme weather conditions, such as search and rescue operations, and in high-security environments, such as military medical facilities.

Field of Art

Molecular biology, immunotherapy, and chimeric antigen receptor (CAR) technology, with expertise in cancer cell detection and targeted cellular therapies

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in molecular biology or bioengineering, experienced in CAR design, antigen targeting, and cellular therapeutic strategies, familiar with NKG2D receptor systems and cancer immunotherapies

Obviousness Rationale

A person of ordinary skill would recognize that extending the anti-MICA CAR technology to specific environmental and operational contexts represents a predictable application of known immunotherapeutic principles. The fundamental CAR design remains consistent with the source patent, while the proposed variations merely adapt the existing technology to novel deployment scenarios. These adaptations leverage standard engineering approaches to expand the utility of the original cellular therapeutic concept.

Obvious Combinations & Variations

Source Patent Element
Anti-MICA chimeric antigen receptor with specific antibody fragment design
PTD Variation
Weather-resistant detector unit for detecting MICA-expressing cancer cells
Obviousness Reasoning
Integrating environmental durability into medical detection systems is a known design optimization technique, representing a predictable extension of existing diagnostic technologies
Source Patent Element
CAR-expressing cellular therapeutic approach
PTD Variation
High-security environment monitoring using secure communication networks
Obviousness Reasoning
Implementing secure communication protocols with medical technologies is a standard approach in sensitive medical and research contexts, representing an obvious technological integration
Source Patent Element
Anti-MICA antibody fragment targeting specific cellular markers
PTD Variation
Portable disaster relief kit with integrated CAR-expressing cell detection system
Obviousness Reasoning
Developing portable medical technologies for emergency response is a predictable application of existing cellular therapeutic and diagnostic principles
Source Patent Element
Polynucleotide encoding chimeric antigen receptor
PTD Variation
Alternative embodiments for space exploration and miniaturized wearable detection systems
Obviousness Reasoning
Adapting medical technologies for extreme environments represents a standard engineering approach of extending existing technological capabilities
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857571 and the published technical disclosure, a person of ordinary skill in the art would find the proposed variations in anti-MICA CAR technology obvious and predictable extensions of existing immunotherapeutic strategies. The disclosed adaptations represent routine engineering modifications that would be apparent to a skilled practitioner without requiring inventive insight beyond the scope of ordinary technological development.

Original Patent Information

Patent NumberUS 11,857,571
TitleAnti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
Assignee(s)The Trustees of Dartmouth College